Fig. 3

Validating the prognostic value of novel immune checkpoints-based signature in an independent cohort of 102 frozen tissue samples. A The distribution of risk score, survival status and gene expression panel. B Overall survival in all patients with LUAD, separated on the basis of risk scores (Kaplan–Meier analysis). C Kaplan–Meier curves of overall survival in patients with early-stage (stage I and II) LUAD, stratified by risk groups. D Kaplan–Meier curves of overall survival in patients with advanced-stage (stage III and IV) LUAD, stratified by risk score. E Kaplan–Meier curves of relapse-free survival in all patients with LUAD, stratified by the risk groups